International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-3 doi: 10.5281/zenodo.8026218
Original Article
A Study of Incidence, Clinical Profile and Complications of Right Ventricular Infarction in Patients with Inferior Wall Myocardial Infarction
 ,
 ,
Published
June 12, 2023
Abstract
Background: Study of incidence, clinical profile and complications of right ventricular infarction in patients with inferior wall myocardial infarction admitted in VIMS hospital. Methods: It is a cross sectional study done at VIMS, Ballari, with a sample size of 100 cases. Patients who fulfilled the inclusion criteria are assessed as per proforma specifically designed for the study. Results: Out of 100 participants with IWMI, 40 of them had RVI. Most of the cases (42.8%) of RVI occurred in the age group of 41-50 years in the RVI group. Out of 100 participants, majority (80%) were male. Only 20% were female. Incidence of risk factors was more among IWMI with RVI than IWMI without RVI and most common risk factor was smoking. Out of 40 patients diagnosed with IWMI with RVI, all presented with chest pain, 16 patients had bradycardia,4 patients presented with shock. Among patients with IWMI with RVI – 6 patients died and among IWMI without RVI, 2 patients died. Conclusion: RVI can occur among people with IWMI in almost one-third of the cases. Identifying risk factors and preventing further progression of disease plays vital role in managing patients with cardiac diseases. Hence risk stratification plays major role in reducing mortality and morbidity associated with MI. One such factor is involvement of right ventricle, that increases the complication rate as well as mortality among patients with inferior wall myocardial infarction.
Recommended Articles
Loading Image...
Volume-4, Issue-3
Citations
2603 Views
111 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved